BioSpace News Archive

At the University of Southern California, Dr. Eun Ji Chung and Dr. Mitchell Gross are tackling cancer at the nanoscale.

“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective therapies,” said April Armstrong, associate dean and professor of dermatology at the University of Southern California.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Jefferies Virtual London Healthcare Conference.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will present data from the ADVANCE-1 trial of AXS-05 in Alzheimer’s disease agitation in an oral session at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference, to be held digitally, November 4-7. AXS-05

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global diagnostics company, today announced third quarter 2020 financial results.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2020 financial results will be released on Tuesday, November 10, 2020 before the U.S. financial markets open.

R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months ended September 30, 2020. Third Quarter 2020 Results: Revenue of $307.2 million, up $6.0 million and 2.0% compared to the same period last year GAAP net income of $5.2 million, compared to net income of $9.2 million in the same period last year Adjusted EBITDA of $50.4 mil

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that it will be reporting its first quarter financial results for the three months ended September 30, 2020 after markets close on Monday, November 16, 2020.

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, announced that it will report its unaudited financial results for the third quarter 2020 before the U.S. market opens on Tuesday, November 17, 2020.